Petra Bretová

ORCID: 0000-0003-1082-433X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Ovarian cancer diagnosis and treatment
  • Cervical Cancer and HPV Research
  • Circular RNAs in diseases
  • Acute Myocardial Infarction Research
  • Venous Thromboembolism Diagnosis and Management
  • Colorectal Cancer Surgical Treatments
  • Cancer Risks and Factors
  • Cancer Genomics and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Endometriosis Research and Treatment
  • Cancer-related molecular mechanisms research

University Hospital Brno
2024-2025

Masaryk University
2025

Charles University
2025

Hospital Universitario Nuestra Señora de Candelaria
2025

University Hospital Hradec Králové
2025

Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups essential. To evaluate SLN in early-stage (International Federation Gynecology and Obstetrics 2009 I-II) cancer, considering subtypes new European Society Gynaecological Oncology (ESGO) risk classification. The SENECA study retrospectively reviewed data from 2139 women stage I-II 66 centers 16...

10.1136/ijgc-2024-005711 article EN other-oa International Journal of Gynecological Cancer 2024-08-17

This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression prognosis in grade 2 endometrioid endometrial carcinoma compared with 1 3 carcinomas. Three European cohort studies were included. Patients known PR status included (n = 400), as patients 602) or 148) Kaplan-Meier Cox regression analyses performed analyze disease-specific disease-free survival. wild-type plus PR-positive showed a similar 7-year survival (95.8% vs 97.5%, p .13),...

10.1016/j.ijgc.2025.101682 article EN cc-by International Journal of Gynecological Cancer 2025-02-01

Our study aims to assess the risk factors associated with bi-lateral sentinel lymph node (SLN) mapping failure in endometrial cancer. The SENECA was a retrospective multi-center international observational that reviewed data from 2139 women clinical stage I-to-II cancer across 64 centers 17 countries. Between January 2021 and December 2022, patients underwent surgical treatment SLN assessment, following guidelines of European Society Gynaecological Oncology. Risk absence were analyzed using...

10.1016/j.ijgc.2025.101771 article EN International Journal of Gynecological Cancer 2025-03-01

Abstract Objectives Endometrial cancer (EC) is the most common malignancy of female genital tract in developed countries, yet preventive screening remains unavailable, and diagnostic approaches are largely limited to symptomatic women. Despite advancements precision oncology, biology precancerous lesions less understood compared advanced disease. To address this gap, we conducted a prospective case-control study analysing uterine lavage fluid from women undergoing evaluation. The included...

10.1186/s13104-025-07173-8 article EN cc-by BMC Research Notes 2025-03-18

The management of cervical cancer during the first trimester pregnancy requires a multidisciplinary approach that considers medical, psychological, and social factors. This report details case patient diagnosed preoperatively with bulky early-stage at nine weeks gestation, an evaluation initially intended for termination. While definitive chemoradiotherapy is standard treatment tumors, strategy, in this case, was influenced by patient's decision to terminate without delay. A radical...

10.7759/cureus.82486 article EN Cureus 2025-04-18

Objective: To evaluate the safety, adequacy, and accuracy of tru-cut biopsy gynaecologic tumours in a population Czech women. Methods: A four-year retrospective study ultrasound-guided was conducted Department Obstetrics Gynaecology, Charles University, Hradec Kralove, Republic. Results: One hundred four women with underwent transvaginal within period. The most common indication for more than one-half suspicion malignancy/inability to exclude malignancy (59, 56.7%). Most were malignant on...

10.3390/diagnostics15091133 article EN cc-by Diagnostics 2025-04-29
Coming Soon ...